KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsShares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) Short-Term Debt repayments: 2009-2023

Historic Short-Term Debt repayments for Teva Pharmaceutical Industries (TEVA) over the last 2 years, with Dec 2023 value amounting to $500.0 million.

  • Teva Pharmaceutical Industries' Short-Term Debt repayments was N/A to $500.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.6 billion, marking a year-over-year change of. This contributed to the annual value of $700.0 million for FY2023, which is N/A change from last year.
  • According to the latest figures from Q4 2023, Teva Pharmaceutical Industries' Short-Term Debt repayments is $500.0 million, which was up 150.00% from $200.0 million recorded in Q3 2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Short-Term Debt repayments peaked at $500.0 million during Q4 2021, and registered a low of $200.0 million during Q3 2023.
  • Its 2-year average for Short-Term Debt repayments is $400.0 million, with a median of $500.0 million in 2023.
  • Data for Teva Pharmaceutical Industries' Short-Term Debt repayments shows a peak YoY increased of 12.87% (in 2021) over the last 5 years.
  • Over the past 3 years, Teva Pharmaceutical Industries' Short-Term Debt repayments (Quarterly) stood at $443.0 million in 2020, then increased by 12.87% to $500.0 million in 2021, then reached $500.0 million in 2023.
  • Its Short-Term Debt repayments stands at $500.0 million for Q4 2023, versus $200.0 million for Q3 2023 and $500.0 million for Q4 2021.